Sucampo Pharmaceuticals: What Can Investors Learn From The Mallinckrodt Acquisition?

12/29/17

Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2B. The cash tender offer equates to $18 per share.

Mallinckrodt to take ownership of Amitiza, a leading medicine servicing the branded constipation market (as well as other molecules for the orphan diseases niche).

This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect